PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known				
Application Number	09/928,213			
Filing Date	August 10, 2001			
First Named Inventor	SHANKARA, Srinivas			
Group Art Unit	1646			
Examiner Name	Unassigned			
Attomey Docket Number	GA0197C			

(use as many sheets as necessary) of

			U.S. PATENT	OCUMENTS	
	0:1-	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Examined	Cite No. <sup>1</sup>	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
	1	US-5,770,428	06-23-98	Wisconsin Alumni Research Foundation	
	2	US-			
	3	US-			
,	4	US-			
	5	US-			
	6	US-			
	7	US-			O EIVED
	8	US-			カドして
	9	US-			RECEIVED  OCT 3 0 2002  TECH CENTER 16
	10	US-			CT 3 0 20
	11	US-			000
	12	US-			TER 10
	13	US-			" CENICI.
	14	US-			TECHO
	15	US-			
	16	US-		1	
	17	US-			
	18	US-			
	19	US-			
	20	US-			

	FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>®</sup>	
	21	WO 97/34613	09-25-97	U of Virginia Patent Foundation	,		
*	22	WO 98/43677	10-08-98	Institut Pasteur			
	23						
	24						
	25	,					
·····	26						
	27						
	28						
	29						

Examiner Signature	Det.	Date Considered	1/12/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional) . <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

OCT 2 8 2002

3 0 2002

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE tion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 09/928,213 Filing Date August 10, 2001 SHANKARA, Srinivas First Named Inventor Group Art Unit 1646 OU DENTER 1600/20 **Examiner Name** Unassigned

(use as many sheets as necessary)

•		•	• • •		T Chadolyhod		יוטטטו ארווא
Sheet	2	of 3		Attorney Docket Number	GA0197C	TEUTIVE	MIEN 10001
<del>ر                                      </del>							
: -		OTHER	PRIOR ART -	NON PATENT LITERATURE I	DOCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>		k, magazine, jo	n CAPITAL LETTERS), title of the a urnal, serial, symposium, catalog, et , publisher, city and/or country whe	tc.), date, page(s), volume-issue		
X	. 30			elanoma Reactive T Cells by Stimulator Colex Class I Fusion Proteins", Cancer Res			
11.							

Examiner Initials	Cite No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X	. 30	KANG, X. et al., "Induction of Melanoma Reactive T Cells by Stimulator Cells Expressing Melanoma Epitope-Major Histocompatibility Complex Class I Fusion Proteins", Cancer Research, January 1997, 57:202-205	
0	31	KOZONO, H. et al., "Production of soluble MHC class II proteins with covalently bound single peptides", Nature, May 1994, 369:151-154	
	32	MOTTEZ, E. et al., "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide Are Highly Immunogenic", The Journal of Experimental Medicine, February 1995, 181:493-502	
	33	POSNETT, D.N. et al., "A Novel Method for Producing Anti-peptide Antibodies", The Journal of Biological Chemistry, February 1988, 263(4):1719-1725	
	34	SAKAI, C. et al., "Melanosomal proteins as melanoma-specific immune targets", Melanoma Research, 1997, 7:83- 95	-
	35	TAM, James P., "Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system", The Proceeding of National Academy of Science, August 1988, 85:5409-5413	
	36	TSAI, V. et al., "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells", The Journal of Immunology, 1997, 158:1796-1802	
	37	ARONOV, S. et al., "Identification of 3'UTR Region Implicated in Tau mRNA Stabilization in Neuronal Cells", Journal of Molecular Neuroscience, 1999, 12:131-145	
	38	HOLCIK, M. and LIEBHABER, S.A., "Four highly stable eukaryotic mRNAs assemble 3' untranslated region RNA- protein complexes sharing cis and trans components", The Proceedings of the National Academy of Science, March 1997, 94:2410-2414	
	39	McGOWAN, K.M. et al., "Tumor Necrosis Factor-alpha Regulation of Glucose Transporter (GLUT1) mRNA Turnover", The Journal of Biological Chemistry, January 1997, 272(2):1331-1337	
X	40	WANG, X. and LIEBHABER, S.A., "Complementary change in cis determinants and trans factors in the evolution of an mRNP stability complex". The EMBO Journal, 1996, 15(18):5040-5051	

Examiner Signature	Date Considered	1/12/04
		\ <del>`</del>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE cotion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

3

Sheet

Complete if Known Application Number 09/928,213 August 10, 2001 Filing Date SHANKARA, Srinivas First Named Inventor **Group Art Unit** 1646 **Examiner Name** Unassigned Attorney Docket Number GA0197C

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
aminer	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	41	KLENERMAN et al., "The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocytes response to human immunodeficiency virus", European Journal of Immunology, 1995, 25:1927-1931		
0				
,,,,,,,				
	1	FCEIVE	V	
		RECEIVE OCT 3.0 TECH CENTER	005	
		001 NTF	16001	
		TECH CENT		

Examiner Signature Date Considered 1/12/04	 		
	$\rho$	l [	1/12/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Substitute for form 1449A/PTO

Sheet

C mplete if Kn wn

Application Number 09/928,213

Filing Date August 10, 2001

First Named Inventor SHANKARA, Srinivas

Group Art Unit 1646

Examiner Name Unassigned

Attorney Docket Number GA0197C

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Cite T 2 Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published. HEEMSKERK, M. et al., "Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human 1 Dendritic Cells", Cellular Immunology, 1999, 195:10-17 TOES, R. et al., "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion", The Proceeding of the National Academy of Science, December 1997, 94:14660-14665 2 WHITTON, J. et al., "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge", Journal of Virology, January 1993, 348-352 3 TECH CENTER 1600/2900

Examiner Signature	2 Jul.	Date Considered	1/12/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.